’Big Short’ Michael Burry de-registers Scion Asset Management
NewcelX Ltd. (NASDAQ:NCXL) announced Thursday that its Board of Directors has appointed Omri Hagai as chief financial officer, effective December 10, 2025. Hagai will succeed Uri Ben Or, who has served as interim CFO and will step down from the position on the same date.
According to a press release statement included in the company’s SEC filing, Ben Or’s departure is not related to any disagreement with NewcelX regarding its operations, policies, or practices. The appointment of Hagai as full-time CFO follows the completion of the merger between NLS Pharmaceutics Ltd. and Kadimastem Ltd.
Hagai brings experience from several public companies in the technology and industrial sectors. From 2016 to 2021, he held multiple roles at Israel Chemicals Ltd. (NYSE:ICL), including assistant controller and disclosure and reporting controller at the company’s global accounting headquarters. Between 2021 and 2023, he served as director of finance at BrainsWay Ltd. (NASDAQ:BWAY). Since 2023, he has been chief financial officer at Saverone 2014 Ltd. (NASDAQ:SVRE).
Hagai holds a bachelor’s degree in business management and accounting from the Hebrew University of Jerusalem and is a certified public accountant in Israel.
The company is headquartered in Zurich, Switzerland. This information is based on a press release statement filed with the Securities and Exchange Commission.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.